Dz Bank Ag Deutsche Zentral Genossenschafts Bank, Frankfurt Am Main Bei Gene, Ltd. Transaction History
Dz Bank Ag Deutsche Zentral Genossenschafts Bank, Frankfurt Am Main
- $83.4 Billion
- Q1 2025
A detailed history of Dz Bank Ag Deutsche Zentral Genossenschafts Bank, Frankfurt Am Main transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Dz Bank Ag Deutsche Zentral Genossenschafts Bank, Frankfurt Am Main holds 5,511 shares of BGNE stock, worth $1.25 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,511Holding current value
$1.25 Million% of portfolio
0.0%Shares
14 transactions
Others Institutions Holding BGNE
# of Institutions
288Shares Held
36.2MCall Options Held
111KPut Options Held
112K-
Baker Bros. Advisors LP New York, NY8.8MShares$1.99 Billion23.78% of portfolio
-
Capital International Investors Los Angeles, CA5.09MShares$1.15 Billion0.24% of portfolio
-
Primecap Management CO Pasadena, CA5.09MShares$1.15 Billion0.94% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.71MShares$615 Million0.09% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E91.03MShares$234 Million7.2% of portfolio
About BeiGene, Ltd.
- Ticker BGNE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,700,000
- Market Cap $23.5B
- Description
- BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...